Physician profile
Stephen Katz
NPI 1619919578
$1,970.36
in general payments reported to CMS, 2019-2025
21 companies · $26.22 in 2025
The $26.22 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $443 · 2020: $33.15 · 2021: $393 · 2022: $843 · 2023: $232 · 2025: $26.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $258.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $281.38 | 2019-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $272.18 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $144.66 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $137.78 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $125.55 | 2022-2023 | Quviviq |
| Axsome Therapeutics, INC. | $124.97 | 2023 | Auvelity |
| Neos Therapeutics, Lp | $123.58 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $121.68 | 2022 | |
| Vanda Pharmaceuticals INC. | $121.64 | 2019-2022 | |
| Alkermes, INC. | $93.72 | 2019 | |
| Sunovion Pharmaceuticals INC. | $85.05 | 2019 | |
| Abbvie INC. | $71.78 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.72 | 2019-2022 | |
| Lundbeck LLC | $46.64 | 2022 | |
| Tris Pharma INC | $35.86 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $23.65 | 2021 | |
| Indivior INC. | $21.23 | 2019 | |
| Corium, LLC | $20.89 | 2022 | |
| Allergan, INC. | $20.62 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.78 | 2019 | |
| Acadia Pharmaceuticals INC | $16.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Katz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.